Fluticasone is generally considered safe during pregnancy, whether used as an inhaler for asthma or as a nasal spray for allergies. Major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG), recommend that pregnant women continue using inhaled corticosteroids like fluticasone rather than risk the well-documented complications of uncontrolled asthma or severe allergies.
What the Evidence Shows About Birth Defects
The most reassuring data comes from large studies pooling thousands of pregnancies. Meta-analyses covering more than 17,000 women exposed to inhaled corticosteroids found no increased risk of congenital malformations compared with women who had asthma but did not use these medications (odds ratio 0.96). A large Danish study comparing over 1,200 women who used inhaled corticosteroids in early pregnancy with nearly 81,000 unexposed women found no increased risk of oral clefts, a malformation sometimes flagged with corticosteroid use.
One nuance worth knowing: women taking high doses (above 1,000 micrograms per day) showed a small but statistically significant increase in the combined rate of major and minor malformations. At standard doses, no such signal appeared. This is one reason clinicians aim to use the lowest effective dose, though the priority remains keeping symptoms well controlled.
The FDA label for fluticasone propionate (Flovent) notes that fluticasone has been detected in umbilical cord blood after delivery, confirming some degree of fetal exposure. Animal studies using injected (not inhaled) fluticasone at high doses produced skeletal abnormalities in rats, mice, and rabbits, but when fluticasone was given by inhalation to rats at roughly half the maximum recommended human dose, it did not cause birth defects. The FDA does not assign a simple letter category (A, B, C) to fluticasone anymore, instead providing a narrative risk summary that acknowledges insufficient human trial data while pointing to the reassuring observational evidence.
Why Stopping Treatment Is Riskier
The biggest danger during pregnancy is often not the medication but the disease it controls. Uncontrolled asthma reduces oxygen delivery to the fetus, and the consequences are measurable. Women with asthma face a significantly higher rate of preterm birth (12.9% versus 9.2% in non-asthmatic women), a 71% higher risk of preeclampsia, and greater likelihood of cesarean delivery. Larger meta-analyses have added low birth weight and small-for-gestational-age infants to that list.
Even a single exacerbation during the first trimester has been linked to a higher risk of congenital malformations (odds ratio 1.48), which is notably higher than the risk associated with the medications themselves. In one study, women who stopped or reduced their inhaled corticosteroids after becoming pregnant gave birth to babies with lower birth weight and shorter birth length compared with women who stayed on therapy. ACOG now explicitly advises clinicians to discourage discontinuation or dose reduction of asthma therapies during pregnancy.
Nasal Spray vs. Inhaler: Absorption Differences
If you use fluticasone as a nasal spray for allergies or rhinitis, fetal exposure is even lower than with an inhaler. Intranasal fluticasone furoate (the active ingredient in brands like Flonase Sensimist and Veramyst) has a systemic bioavailability of less than 1%. Most of the sprayed dose is swallowed, then broken down extensively by the liver before it can reach the bloodstream. At the standard recommended dose, the amount entering circulation is negligible.
A review of intranasal corticosteroid safety in pregnancy found no significant association between nasal fluticasone (either the propionate or furoate form) and congenital organ malformations. The review concluded that intranasal fluticasone furoate is safe at recommended therapeutic doses after proper evaluation. Budesonide is sometimes listed as a first-choice nasal spray in pregnancy simply because it has the longest track record of human data, but fluticasone is considered a reasonable alternative.
How Fluticasone Compares to Budesonide
Budesonide has historically been the most-studied inhaled corticosteroid in pregnancy, which is why some guidelines single it out. However, current expert reviews list both fluticasone and budesonide as preferred inhaled corticosteroids during pregnancy. If you were already using fluticasone before becoming pregnant, switching to budesonide is not necessary and could destabilize your asthma control during a period when stability matters most.
ACOG’s position reinforces this: inhaled corticosteroids as a class should be a mainstay of asthma treatment in all pregnant women, ideally combined with a rapid-onset bronchodilator. The emphasis is on maintaining whatever regimen was working before conception.
Fluticasone While Breastfeeding
After delivery, fluticasone remains compatible with breastfeeding. No adverse effects in breastfed infants have been reported with any inhaled or nasal corticosteroid. Although actual milk levels of fluticasone have not been formally measured, the extremely low systemic absorption means the amount reaching breast milk is likely too small to affect a nursing infant. Expert consensus considers both inhaled and nasal corticosteroids acceptable during breastfeeding.
Practical Takeaways for Pregnancy
- Continue your current regimen. If fluticasone was controlling your asthma or allergies before pregnancy, staying on it is safer than stopping.
- Use the lowest effective dose. Standard doses show no increased malformation risk. Very high doses (above 1,000 micrograms daily of inhaled corticosteroid) carry a small signal worth discussing with your provider.
- Nasal sprays carry minimal risk. Less than 1% of the dose reaches your bloodstream, making fetal exposure extremely low.
- Asthma exacerbations are the real threat. A flare during the first trimester poses a greater risk to fetal development than the medication itself.